What is the Purpose of this Study?
This study focuses on people with locally advanced or metastatic, clear cell renal cell carcinoma (a specific type of kidney cancer) who have gotten worse after treatment with at least 1 but no more than 4 previous chemotherapies or other therapy. The purpose of the study is to identify the highest safe dose (the maximum tolerated dose and/ or recommended dose for the next phase of testing) of HC-7366 capsules and/or belzutifan tablets and/or cabozantinib capsules in these patients. Researchers aim to understand how well the drugs work together and how safe they are when given to participants. Study procedures also include physical exam, blood sample collection, electrocardiogram, and computed tomography. The use of HC-7366, belzutifan, and cabozantinib in this study is investigational.
Eligibility
- * Has diagnosis of locally advanced (inoperable) or metastatic RCC with a predominant clear cell component
- * Be age 18 years or older (male or female) at the time of consent
Where can I participate?
- CS Cancer at Beverly Hills : Maria Tarallo
- CS Cancer at Cedars-Sinai Medical Center : Maria Tarallo
More about this Clinical Trial
What is the full name of this clinical trial?
HC366-RCC2311: A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC7366 in Combination with Belzutifan in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma